Search

1 to 10 of 230
Sort by

Event
Immuno-Oncology Young Investigators' Forum

Presented by The University of Texas MD Anderson Cancer Center and Creative Educational Concepts, Inc. (CEC) in collaboration with the Society for Immunotherapy of Cancer. This program is ideally suited for North American-based junior faculty, fellows, and postdoctoral researchers (MDs, DOs,...

 04-16-2020 08:00 - 04-18-2020 20:00 CT
 Houston TX


Library Entry
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer

Bone metastases (BoM) are a negative prognostic factor in non-small-cell lung cancer (NSCLC). Beyond its supportive role, bone is a hematopoietic organ actively regulating immune system. The authors hypothesized that BoM may influence sensitivity to immunotherapy. They conclude that BoM impairs...



Library Entry
Intratumoral immunoglobulin isotypes predict survival in lung adenocarcinoma subtypes

The role of tumor-infiltrating B-cells (TIBs) and intratumorally-produced antibodies in cancer-immunity interactions essentially remains terra incognita . In particular, it remains unexplored how driver mutations could be associated with distinct TIBs signatures and their role in tumor...


Library Entry
Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment

There is strong evidence that immunotherapy-mediated tumor rejection can be driven by tumor-specific CD8+ T cells reinvigorated to recognize neoantigens derived from tumor somatic mutations. Thus, the frequencies or characteristics of tumor-reactive, mutation-specific CD8+ T cells could be used...


Library Entry
Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer

PD-1/PD-L1 blockade has received approval for clinical application due to its encouraging benefit with improving prognosis in selected populations. Unfortunately, the response to immunotherapy for many patients remains unsatisfactory. It remains a great challenge to generate potential...





Library Entry
Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges

While immune checkpoint inhibitors (ICIs) have had a major impact on the clinical outcome of several solid tumors, including non-small cell lung cancer, the potential role of ICIs is currently under investigation in SCLC and some promising data are available. The authors summarize the current...